Mar 12, 2026 4:01 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 12, 2026 9:00 am EDT Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Mar 10, 2026 9:25 am EDT Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Mar 09, 2026 8:30 am EDT Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
Feb 24, 2026 9:00 am EST Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Jan 20, 2026 9:15 am EST Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Dec 16, 2025 4:05 pm EST Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Dec 05, 2025 6:15 am EST Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Dec 03, 2025 7:20 am EST Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy